Conditions: Adult Attention-Deficit Hyperactivity Disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 26
Healthy volunteers: no

Brief summary:
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride.

The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in adults.

Detailed description:
The purpose of this study is to determine whether guanfacine hydrochloride used as an adjunct therapy (to subjects' current stimulant medication) would bring about a statistically significant improvement in AD/HD symptoms.

Arms:
arm 1: 1. mg Guanfacine Hydrochloride (orally, QD)
2. mg Guanfacine Hydrochloride (orally, QD)
3. mg Guanfacine Hydrochloride (orally, QD)
4. mg Guanfacine Hydrochloride (orally, QD)
5. mg Guanfacine Hydrochloride (orally, QD)
6. mg Guanfacine Hydrochloride (orally, QD) arm 2: 1. mg Placebo
2. mg Placebo
3. mg Placebo
4. mg Placebo
5. mg Placebo
6. mg Placebo

Interventions: intervention 1: Guanfacine Hydrochloride intervention 2: Placebo
Intervention descriptions: intervention 1: 1. mg Guanfacine Hydrochloride (orally)
2. mg Guanfacine Hydrochloride (orally)
3. mg Guanfacine Hydrochloride (orally)
4. mg Guanfacine Hydrochloride (orally)
5. mg Guanfacine Hydrochloride (orally)
6. mg Guanfacine Hydrochloride (orally) intervention 2: Placebo of matching mg

Protocol document: